ClinicalTrials.gov record
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

ClinicalTrials.gov ID: NCT06581406

Public ClinicalTrials.gov record NCT06581406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Study identification

NCT ID
NCT06581406
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Replimune, Inc.
Industry
Enrollment
280 participants

Conditions and interventions

Interventions

  • Ipilimumab Biological
  • Nivolumab Biological
  • RP2 Biological

Biological

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 16, 2024
Primary completion
Dec 31, 2029
Completion
Sep 30, 2031
Last update posted
Apr 1, 2026

2024 – 2031

United States locations

U.S. sites
29
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
HonorHealth Research Insisute Scottsdale Arizona 85258 Recruiting
UC San Diego Moores Cancer Center La Jolla California 92037 Recruiting
The Angeles Clinic and Research Institute Los Angeles California 90025 Recruiting
University of California Los Angeles Los Angeles California 90095 Recruiting
Stanford Cancer Institute Palo Alto California 94304 Recruiting
University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) Aurora Colorado 80045 Recruiting
The Melanoma & Skin Cancer Institute Englewood Colorado 80113 Recruiting
Georgetown University Medical Center Washington D.C. District of Columbia 20007 Recruiting
Mayo Clinic - Jacksonville FL Jacksonville Florida 32224 Recruiting
Sylvester Comprehensive Cancer Center Miami Florida 33136 Recruiting
Emory Winship Cancer Institute Atlanta Georgia 30322 Recruiting
Northwestern Memorial Hospital Chicago Illinois 60611 Recruiting
University of Chicago Medical Center Chicago Illinois 60637 Recruiting
University of Iowa Iowa City Iowa 52242 Recruiting
Massachusetts General Hospital Boston Massachusetts 02114 Recruiting
Mayo Clinic Rochester Rochester Minnesota 55905 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Duke University Medical Center Durham North Carolina 27710 Recruiting
The Ohio State University Columbus Ohio 43210 Recruiting
Thomas Jefferson University Philadelphia Pennsylvania 19107 Recruiting
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 Recruiting
The West Clinic, PLLC dba West Cancer Center Germantown Tennessee 38138 Recruiting
University of Tennessee Medical Center Knoxville Tennessee 37920 Recruiting
Sarah Cannon Research Institute Nashville Tennessee 37203 Recruiting
Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic) Nashville Tennessee 37232 Recruiting
UT Southwestern Medical Center Dallas Texas 75390 Recruiting
The University Of Texas Md Anderson Cancer Center Houston Texas 77030 Recruiting
Fred Hutchinson Cancer Center Seattle Washington 98109 Recruiting
University Of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06581406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2026 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06581406 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →